Search results for: Market Access
Filter search results
OHE Lunchtime Seminar: Price Regulation of Generics and Drug Shortages
21 November 2018
…the pharmaceutical marketplace in Canada. This includes price-cap regulations on brand-name and generic drug prices and their impact on the pharmaceutical market dynamics in Canada. View the full seminar invite here….
Economic Post-Launch Studies: Matching the Desirable with the Feasible
1 September 2006
Whilst companies routinely conduct post-marketing surveillance studies to collect data on adverse events, the focus of this report is on ‘post-launch’ studies conducted to collect information about health outcomes, including…
The WHO Technical Report on the Pricing of Cancer Medicines: Missing a Central Role for Value Assessment
8 April 2019
…crucial to increasing access. It should oppose the Report’s advocacy of transparency of on-patent pricing, which will reduce access to medicines. At the end of 2018 a WHO Technical Report…
Indication-Based Pricing: Are We All Onboard?
12 May 2020
…experience of IBP were more positive than those without. 70% of survey respondents believed IBP would expand patient access to medicines. However, three-quarters of respondents believed that expanded patient access…
European Union Pharmaceutical Markets: A Case for Differential Pricing?
11 August 2015
…confidential. Implementing differential pricing under this option would obviously require limitations to price transparency. The article concludes discussing the feasibility of implementing these possible solutions. Access the full article here….
Is It Time to Reconsider the Role of Co-Payments in Europe?
11 January 2012
…gain access to care. The second has been to raise additional revenue to reduce the burden on the insurer. An unintended consequence, however, has been that co-payments have made access…
Time Trends in NICE HTA Decisions
1 January 2012
…for Health and Clinical Excellence (NICE) was to reduce inequalities in access to innovative care and ensure more rapid access to medicines identified as being of value to the NHS….
A Prescription for Green Healthcare Delivery: Insights from an Expert Sustainability Webinar
19 July 2023
…there are challenges, including the need for rapid market access, sustainability can lead to efficiency gains and cost savings. Producing environmentally friendly, clinically- and cost-effective medicines can provide a competitive…
Differential Pricing – A Win-Win Solution?
2 March 2011
…higher prices have been established elsewhere’ thus delaying access by patients to new medicines. In extreme cases, companies may decide to not market a medicine at all in a particular…